Truepill’s Sid Viswanathan (left) is out as CEO. His cofounder Umar Afridi, who previously held that role, left last year.
Timothy Archibald/The Forbes Collection
Not quite 18 months after being named CEO of Truepill, cofounder Sid Viswanathan is gone. The company, worth $1.6 billion at its last equity funding round, faces an uncertain future with a cash squeeze and DEA investigation.
Truepill cofounder Sid Viswanathan is out as CEO of the tech-enabled pharmacy as the company’s troubles mount.
“Earlier this week was my last day as CEO of Truepill,” Viswanathan wrote in a LinkedIn post earlier today. “This month marks nine years since I left my last job to pursue a crazy startup idea with Umar Afridi. It has been nothing short of an exhilarating ride full of all the ups and downs you would expect, and then some.”
The San Mateo, California-based company has not publicly named a new replacement. Truepill did not respond to requests for comment. Paul Greenall, the company’s president, would seem to be the obvious candidate to be CEO or acting CEO. He joined the company as chief business officer last July and was promoted to president later in the year. Greenall did not respond to requests for comment.
Viswanathan said in his LinkedIn post that he was “really proud” of what they’d built at Truepill and that he had “no clue” what he would be doing next. “I’ll be taking some time off to recharge and figure out the next chapter,” he wrote. Viswanathan did not respond to voicemail, text or email messages seeking additional comment.
Forbes first profiled Truepill as part of the Next Billion-Dollar Startups list in 2019, an oddity in the list as it had raised just $13 million in venture funding at the time. Viswanathan, an Indian immigrant who sold his previous startup to LinkedIn, and Afridi, a former pharmacist who was then the company’s CEO, set out to upend the heavily regulated pharmacy business with technology. The startup shipped its first prescriptions in 2016. By 2018, its revenue had reached $48 million, helped by the fast growth of direct-to-consumer customers like Nurx, which sells birth control, and Hims, which focuses on remedies for hair loss, erectile dysfunction and acne. To consumers, these Instagrammable health products don’t look like drugs, and their subscription boxes often contain a mix of both prescription and over-the-counter products. But if there’s even a vial of prescription pills going out in the mail, the startup sending it needs a pharmacy to fulfill the order.
By 2019, the company had doubled its revenue to nearly $100 million as it expanded its customer base beyond direct-to-consumer medications to prescriptions that treat more serious illnesses. It expected closer to $200 million in revenue for 2020.
The big bet, of course, was telemedicine. As it looked to increase beyond pharmacy, it rolled out at-home testing services, for example, just one piece of what Viswanathan and Afridi believed would be a broad switch to online healthcare. “We envision a future where 80% of healthcare is virtual,” Viswanathan told trade publication Fierce Healthcare in 2020.
In October 2021, the company raised a $142 million Series D at a $1.6 billion valuation. At that point, the company had raised a total of $256 million in equity funding from investors that include Initialized Capital and TI Platform Management.
But competition has gotten tougher as other tech-enabled pharmacies, like Alto and Capsule, have cropped up. Just over a year later, Truepill needed another infusion of cash, raising $50 million in convertible debt in November 2022, according to venture-capital database PitchBook. It has since faced other difficulties as it has been rapidly burning through cash–at a rate of $12 million per month–according to a May 2023 article in Insider. It conducted four rounds of layoffs and closed three of its pharmacies, while downsizing a fourth, according to Insider’s reporting.
The problems ran deeper than just a cash squeeze as the startup also came under scrutiny from the federal government. In 2022, the U.S. Drug Enforcement Agency alleged that Truepill had “wrongfully filled” thousands of prescriptions for controlled substances, including the ADHD medication Adderall, a stimulant. The investigation stemmed from Truepill’s work filling prescriptions for the Softbank-backed mental health startup Cerebral, which was under investigation by the U.S. Department of Justice over its prescribing practices. The DEA alleged Truepill was filling prescriptions in excess of 90-day supply limits, as well as prescriptions written by providers without the proper state licensing. “We are confident we will be able to demonstrate the absence of wrongdoing,” Viswanathan told The Wall Street Journal in December. (The DEA did not respond to a request for an update on the status of the investigation.)
When he left the company, Viswanathan had been CEO for just under 18 months. He took over as CEO from Afridi in February 2022. Afridi left Truepill at that point, according to his LinkedIn profile. Afridi did not respond to an email message seeking comment. At the time Viswanathan took over, the company said that it had processed more than two million diagnostic tests, shipped more than 10 million prescriptions and was facilitating up to 50,000 telehealth visits per week.